

### **REMARKS**

The specification has been amended to include the attached Figures.

Attached are marked-up copies of the originally-filed figures wherein amendments have been shown in hand-written text.

Support for the amendments to Figure 3 find support, for example, on page 29, lines 12-35 wherein the experimental results of Figure 3 are described. Specifically, the specification teaches the following (emphasis added):

The E2F tumour cell line used in E above was treated with either H2\* or H4\* peptides alone or in combination with etoposide. At 24 hours post treatment cellular morphology was noted and those with a rounded abnormal appearance were scored as dead. Additional experiments using trypan blue exclusion as a measure of viability yielded similar results. Cultures treated with the H4\* peptide showed background levels cell death whereas cultures treated with H2\* or etoposide alone showed significantly more death, approximately 15% (FIG. 3). Cultures treated with H2\* and etoposide together showed much higher levels of cell death indicating an additive effect of both agents.

Since H2 induces DNA laddering during apoptosis, the integrity of the genomic DNA was assessed at 24 and 48 hours post treatment. After 24 hours DNA damage was observed in H2\* treated cultures but not in cells exposed to H4\* or etoposide. Although etoposide induced cell death in a similar manner to H2\* it did not stimulate DNA laddering consistent with a cytotoxic rather than an apoptotic mechanism of action. Interestingly the amount of DNA laddering in H2\*/etoposide treatments was greater than H2\* alone, a phenomena which was not apparent in H4\*/etoposide treatments. This effect was more evident at 48 hours where the activity of H2\* alone was much lower.

One of ordinary skill in the art reviewing the above and originally-filed Figure 3 will appreciate that the label amendments made to Figure 3 in the attached do not enter new matter.

LA THANGUE et al  
Appl. No. 09/900,147  
July 21, 2004

The Examiner is requested to advise the undersigned in the event anything further is required in this regard.

Acceptance of the formal drawings, or specific objection of the same in the Examiner's next communication, along with an indication of allowance of the claims, are requested.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100



FIG. 1

|              |    | 163                                   | 199 | Activity |     |
|--------------|----|---------------------------------------|-----|----------|-----|
|              |    | :                                     | :   | Dimer    | DB  |
| SEQ ID NO: 1 | H  | KNIRRRVYDALNVLAMNIIISKEKKEIKWIGLPTNSA |     | +        | +   |
| SEQ ID NO: 2 | H1 | RRRVYDALNVL                           |     | -        | -   |
| SEQ ID NO: 3 | H2 | RRRVYDALNVLAMNIIISK                   |     | +        | +   |
| SEQ ID NO: 4 | H3 | NVLAMNIIISKEKKEIKWIG                  |     | +        | +/- |
| SEQ ID NO: 5 | H4 | EKKEIKWIGLPTNSA                       |     | -        | -   |
| SEQ ID NO: 6 | H5 | RVYDALNVLAMNIIIS                      |     | +        | +/- |
| SEQ ID NO: 7 | H6 | RRVYDALNVLAMN                         |     | -        | -   |
| SEQ ID NO: 8 | H7 | YDALNVLAMNIIISKEKKEIKWIGLPTNSA        |     | +        | +   |

1/3

Marked-up copy

SEQ ID NO: 9 18 NESAYDQKNIRR  
SEQ ID NO: 10 15 NLVQRNRQAEQQARR  
SEQ ID NO: 11 17 EVERQRRLERIKQKQ

FIG. 2







FIG. 3



E = etoposide